Latest news

  • 02 April 2020

    Sensorion reports full-year 2019 financial results and business update Solid €30m cash position at year end and runway increased to beginning of Q3 2021. Read

  • 13 March 2020

    Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has one clinical stage drug candidate for sudden sensorineural hearing loss, two preclinical gene therapy programs and a cutting-edge inner ear R&D platform. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more